Trial Information
An Extension Study for Patients Previously Treated With ARQ 501
Inclusion Criteria:
- Signed written informed consent
- Has previous participated in a clinical trial with ARQ 501 and is eligible for
continued treatment
Exclusion Criteria:
- Have not received previous treatment with ARQ 501 under a treatment protocol
- Uncontrolled intercurrent illness, uncontrolled infection or psychiatric
illness/social situations that would limit compliance with study requirements
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
Outcome Time Frame:
No time frame
Safety Issue:
Yes
Principal Investigator
Neil Nathan Senzer, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Mary Crowley Medical Research Center
Authority:
United States: Food and Drug Administration
Study ID:
ARQ 501-115
NCT ID:
NCT00622063
Start Date:
December 2006
Completion Date:
Related Keywords:
- Cancer
- cancer, solid tumor
Name | Location |
Mary Crowley Medical Research Center |
Dallas, Texas 75246 |